Management of patients on chronic glucocorticoid therapy: An endocrine perspective

Primary Care - Clinics in Office Practice

Volumn 30, Issue 3, 2003, Pages 593-605

  Trence, Dace L ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANABOLIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; DEXAMETHASONE; ETIDRONIC ACID; FIBRIC ACID DERIVATIVE; GLUCOCORTICOID; HYDROCORTISONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INSULIN ASPART; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; MEDROXYPROGESTERONE; NICOTINIC ACID; OMEGA 3 FATTY ACID; PREDNISOLONE; PREDNISONE; TETRACOSACTIDE; THIAZIDE DIURETIC AGENT; VITAMIN D;

ACNE; ADRENAL DISEASE; ADRENAL SUPPRESSION; ADRENAL WITHDRAWAL SYNDROME; ATHEROGENESIS; AVASCULAR NECROSIS; CATARACT; CORTICOSTEROID INDUCED OSTEOPOROSIS; DIABETES MELLITUS; DIET RESTRICTION; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG USE; DYSLIPIDEMIA; DYSPEPSIA; EUPHORIA; FLUID RETENTION; HORMONE SUBSTITUTION; HUMAN; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; HYPOPHYSIS ADRENAL SYSTEM; INSOMNIA; INSULIN TREATMENT; LONG TERM CARE; MOOD DISORDER; OBESITY; OPEN ANGLE GLAUCOMA; OSTEOPENIA; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SIDE EFFECT; SKIN BRUISING; SKIN DISEASE; SKIN THINNING; TREATMENT INDICATION; VISUAL IMPAIRMENT; WEIGHT GAIN;

EID: 0141764684     PISSN: 00954543     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0095-4543(03)00038-1     Document Type: Review

References (71)

1. Hensch PS, Kendall EC, Slocumb CH, et al. The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone: compound E) and of pituitary adrenocorticotrophis hormone on rheumatoid arthritis. Proc Staff Meet Mayo Clin 1949;24:181-97.
2. von Vollenhoven RF. Corticosteroids in rheumatic disease. Postgrad Med 1998;103:137-42.
3. Bressler P, De Fronzo RA. Drugs and diabetes. Diabetes Rev 1994;2:53-84.
4. Mokshagundam SP, Peiris AN. Drug induced disorders of glucose metabolism. In: Leahy JL, Clark NG, Cefalu WT, editors. Medical management of diabetes mellitus. New York: Marcel Decker; 2000. p. 201-15.
5. Welbourn RB, Montgomery DA, Kennedy TL. The natural history of treated Cushing's syndrome. Br J Surg 1971;58:1-16.
6. Trence DL, Hirsch IB. Hyperglycemic crises in diabetes mellitus type 2. Endocrinol Metab Clin North Am 2001;30:817-31.
7. Bedalov A, Balasubramanyam A. Glucocorticoid-induced ketoacidosis in gestational diabetes: sequelae of the acute treatment of preterm labor. Diabetes Care 1997;20:922-924.
8. Pagano G, Cavallo-Perin P, Cassader M, et al. An in vivo and in vitro study of the mechanism of prednisone induced insulin resistance in healthy subjests. J Clin Invest 1983;72:1814-20.
9. Shamoon H, Soman V, Sherwin R. The influence of acute physiological increments of cortisol on fuel metabolism and insulin binding to monocytes in normal humans. J Clin Endocrinol Metab 1980;50:495-501.
10. Rizza RA, Mandarino LJ, Gerich JE. Cortisol-induced insulin resistance in man: impaired suppression of glucose production and stimulation of glucose utilization due to a post-receptor defect of insulin action. J Clin Endocrinol Metab 1982;54:131-8.
11. Latham R, Lancaster AD, Covington JF, et al. The association of diabetes and glucose control with surgical site infection among cardiothoracic surgery patients. Infect Control Hosp Epidemiol 2001;22:607-12.
12. Pagano G, Lombardi A, Ferris GM, et al. Acute effect of prednisone and deflazacort on glucose tolerance in prediabetic subjects. Eur J Clin Pharmacol 1982;22:469-71.
13. Leahy JL. Detrimental effects of chronic hyperglycemia on the pancreatic beta-cell. In: LeRoith D, Taylor SI, Olefsky JM, editors: Diabetes mellitus. Philadelphia: Lippincott-Raven Publishers; 1996. p. 103-13.
14. DeWitt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus. JAMA 2003;289:2265-9.
15. Yki-Jarvinen H, Kauppila M, Kujensun E, et al. Comparison of insulin regimens in patients with non-insulin dependent diabetes mellitus. N Engl J Med 1992;327:1426-33.
16. Yki-Jarvinen H, Ryysy L, Nikkila K, et al. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus: a randomized control trial. Ann Intern Med 1999;130:389-96.
17. Dequecker J, Westhovens R. Low dose corticosteroid associated osteoporosis in rheumatoid arthritis and its prophylaxis and treatement: bones of contention. J Rheumatol 1995;22:1013-9.
18. Saag KG. Low-dose corticosteroid therapy in rheumatoid arthritis: balancing the evidence. Am J Med 1997;103(Suppl 6A):31S-9S.
19. Adami S, Fossaluzza V, Rossini M, et al. The prevention of corticosteroid-induced osteoporosis with nandrolone decanoate. J Bone Miner Res 1991;15:72-81.
20. Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 1990;112:352-64.
21. Butler RC, Davie MW, Worsfold M, et al. Bone mineral content in patients with rheumatoid arthritis: relationship to low dose steroid therapy. Br J Rheumatol 1991;30:86-90.
22. de Deuxchaines CN, Devogelaer JP, Esselincks W, et al. The effect of low dosage glucocorticoids on bone mass in rheumatoid arthritis: a cross-sectional and a longitudinal study using single photon adsorptometry. Adv Exp Med Biol 1984;171:210-39.
23. Julian BA, Laskow DA, Dubrovsky J, et al. Rapid loss of vertebral mineral density after renal transplantation. N Engl J Med 1991;325:544-50.
24. LoCascio V, Bonucci E, Imbimbo B, et al. Bone loss after glucocorticoid therapy. Calcif Tissue Int 1984;36:435-8.
25. Lukert BP, Raisz LG. Glucocorticoid induced osteoporosis. Rheum Dis Clin North Am 1994;20:629-51.
26. Sambrook PN, Birmingham J, Kempler S, et al. Corticosteroid effects on proximal femur bone loss. J Bone Miner Res 1990;5:1211-6.
27. Sambrook PN, Eisman JA, Champion GD, et al. Determinants of axial bone loss in rheumatoid arthritis. Arthritis Rheum 1987;30:721-6.
28. Shane E, Rivas MD, Silverberg SJ, et al. Osteoporosis after cardiac transplantation. Am J Med 1987;94:257-64.
29. Schaadt O, Bohr H. Loss of bone mineral in axial and peripheral skeleton in aging, prednisone treatment and osteoporosis. In: Dequeker JV, Johnston CC Jr, editors. Non-invasive bone measurements: methodologic problems. Oxford: IRL Press; 1982. p. 207-14.
30. Reid IR, Evans MC, Stapleton J. Lateral spine densitometry is a more sensitive indicator of glucocorticoid induced bone loss. J Bone Miner Res 1992;7:1221-5.
31. Reid IR. Steroid osteoporosis. Clinical day handout 57-65. Presented at the annual meeting of the American Society of Bone and Mineral Research. San Diego, 1991.
32. Hodsman AB, Toogood JH, Jennings B, et al. Differential effects of inhaled budesonide and oral prednisolone on serum osteocalcin. J Clin Endocrinol Metab 1991;72:530-4.
33. Teelucksingh S, Padfield PL, Tibi L, et al. Inhaled corticosteroids, bone formation, and osteocalcin. Lancet 1991;2:60-1.
34. Nielsen HK, Charles P, Mosekilde L. The effects of single oral doses of prednisone on the circadian rhythm of serum osteocalcin in normal subjects. J Clin Endocrinol Metab 1988;67:1025-30.
35. Hahn TJ, Halstead LR, Baran DT. Effects of short term glucocorticoid administration on intestinal calcium: absorption and circulating vitamin D metabolite concentrations in man. J Clin Endocrinol Metab 1981;52:11-5.
36. Kimberg DV, Baerg RD, Gerson E, et al. Effect of cortisone treatment on the active transport of calcium by the small intestine. J Clin Invest 1971;50:1309-21.
37. Lund B, Storm TL, Lund B, et al. Bone mineral loss, bone histomorphometry and vitamin D metabolism in patients with rheumatoid arthritis on long-term glucocorticoid treatment. Clin Rheumatol 1985;4:143-9.
38. Dempster DW, Arlot MA, Meunier PJ. Mean wall thickness and formation periods of trabecular bone packets in corticoid-induced osteoporosis. Calcif Tissue Int 1983;35:401-7.
39. Jee WS, Park HZ, Roberts WE, et al. Corticosteroid and bone. Am J Anat 1977;129:477-480.
40. Lanc NE, Lukert B. The science and therapy of glucocorticoid-induced bone loss. Endocrinol Metab Clin North Am 1998;27:465-83.
41. Thompson JT, Modin G, Arnaud C, et al. Not all postmenopausal women on chronic steroids and estrogen are osteoporotic: risk factors for osteoporosis. Calcif Tissue Int 1997;61:377-81.
42. American College of Rheumatology. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 1996;39:1791-801.
43. Gluck OS, Murphy WA, Hahn TJ, et al. Bone loss in adults receiving alternate day glucocorticoid therapy: a comparison with daily therapy. Arthritis Rheum 1981;24:892-8.
44. Adams JS, Wahl TO, Lukert BP. Effects of hydrochlorothiazide and dietary sodium restriction on calcium metabolism in corticosteroid treated patients. Metabolism 1981;30:217-21.
45. Adachi J, Benson WG, Brown J, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997;337:382-7.
46. Adachi J, Cranney A, Goldsmith CH, et al. Intermittent cyclical therapy with etidronate in the prevention of corticosteroid-induced bone loss. J Rheumatol 1994;21:1922-6.
47. Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid induced osteoporosis. N Engl J Med 1998;339:292-9.
48. Bentsen Y, Jamart J, Esselinkx W, et al. Primary prevention of glucocorticoid-induced osteoporosis with intavenous pamidronate and calcium: a prospective controlled 1-year study comparing single infusion given once every three 3 months, and calcium. J Bone Miner Res 2001;16:104-12.
49. Reid IR, Wattie DJ, Evans MC, et al. Testosterone therapy in glucocorticoid-treated men. Arch Intern Med 1996;156:1173-7.
50. Lukert BP, Johnson BE, Robinson RG. Estrogen and progesterone replacement therapy reduces glucocorticoid-induced bone loss. J Bone Miner Res 1992;7:1063-9.
51. Adinoff AD, Hollister JR. Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med 1983;309:265-8.
52. Grecu EO, Weinshelbaum A, Simmons R. Effective therapy of glucocorticoid-induced osteoporosis with medroxyprogesterone acetate. Calcif Tissue Int 1990;46:294-9.
53. Healey J, Paget S, Williams-Russo P, et al. Randomized trial of salmon calcitonin to prevent bone loss in corticosteroid treated temporal arteritis and polymyalgia rheumatica. Calcif Tissue Int 1996;58:73-80.
54. Ettinger WH Jr, Hazzard WR. Prednisone increases very low density lipoprotein in healthy men. Metabolism 1988;37:1055-8.
55. Taskinen MR, Ohta H, Maekawa M, et al. Short-term effects of prednisone on serum lipids and high density lipoprotein subfractions in normolipidemic healthy men. J Clin Endocrinol Metab 1988;67:291-9.
56. Kasiske BL, Umen AJ. Persistent hyperlipidemia in renal transplant patients. Medicine (Baltimore) 1987;66:309-16.
57. Tyrrell JB. Glucocorticoid therapy. In: Felig P, Baxter JD, Frohman LA, editors. Endocrinology and metabolism. 3rd edition. New York: MacGraw-Hill; 1995. p. 855-82.
58. Zimmerman J, Fainaru M, Eisenberg S. The effects of prednisone therapy on lipoproteins and apolipoproteins: a prospective study. Metabolism 1984;33:521-6.
59. Ettinger WH, Goldberg AP, Applebaum-Bowden D, et al. Dyslipoproteinemia in systemic lupus erythematosus: effect of corticosteroids. Am J Med 1987;83:503-8.
60. Ettinger WH Jr, Hazzard WR. Elevated apoplipoprotein-B levels in corticosteroid-treated patients with systemic lupus erythematosus. J Clin Endocrinol Metab 1988;67:425-8.
61. Austen JL, Shifrin FA, Bartucci MR, et al. Effects of fluvastatin on hyperlipidemia after renal transplantation: influence of steroid therapy. Ann Pharmacother 1996;30:1386-9.
62. Castelao AM, Grinyo JM, Castenieras MJ, et al. Effect of pravastatin in the treatment of hypercholesterolemia after renal transplantation under cyclosporine and prednisone. Transplant Proc 1995;27:2217-20.
63. Kobashigawa JA, Kasiske BL. Hyperlipidemia in solid organ transplantation. Transplantation 1997;63:331-8.
64. Schmidt EB, Varming K, Svaneborg N, et al. n-3 polyunsaturated fatty acid supplementation in men with moderate and severe hypertriglyceridemia: a dose response study. Ann Nutr Metab 1992;36:283-7.
65. Durrington PN, Bhatnagar D, Mackness MI, et al. An omega-3 fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridemia. Heart 2001;85:544-8.
66. Plotz CM, Knowlton Al, Ragan C. The natural history of Cushing's syndrome. Am J Med 1952;13:597-614.
67. Stoffer LJ, Iannaccone A, Gabrilove JL. Cushing's syndrome: a study of fifty patients. Am J Med 1961;300:129-35.
68. Luton JP, Mahoudeau JA, Bouchard P, et al. Treatment of Cushing's disease by O,p'DDD: survey of 62 cases. N Engl J Mcd 1979;300:459-64.
69. Streck WF, Lockwood DH. Pituitary adrenal recovery following short term suppression with corticosteroids. Am J Med 1979;66:910-4.
70. Byyny RL. Withdrawal from glucocorticoid therapy. N Engl J Med 1976;295:30-2.
71. Vathsala A, Weinberg RB, Schoenberg L, et al. Lipid abnormalities in cyclosporine-treated renal transplant recipients. Transplantation 1989;48:37-43.